CN1180811C - Chinese medicine composition for treating tumor - Google Patents
Chinese medicine composition for treating tumor Download PDFInfo
- Publication number
- CN1180811C CN1180811C CNB01139823XA CN01139823A CN1180811C CN 1180811 C CN1180811 C CN 1180811C CN B01139823X A CNB01139823X A CN B01139823XA CN 01139823 A CN01139823 A CN 01139823A CN 1180811 C CN1180811 C CN 1180811C
- Authority
- CN
- China
- Prior art keywords
- radix
- compositions
- powder
- following materials
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a Chinese medicine composition for treating tumors. Qiankunling A granules and Qiankunling B granules are prepared from musk, Qianjinzi, Kunjinzi, Lingjinzi, jiuxian powder and eighteen powder. The present invention has the advantages of wide scope of treatment, outstanding treating effects and no toxic or side effects. The present invention has particularly obvious effects on tumors of the digestive system, the secretory system and the respiratory system, such as stomach cancer, intestinal cancer, esophagus cancer, pancreatic cancer, liver cancer and lung cancer.
Description
Technical field
The present invention relates to a kind ofly treat tumor, especially treat the Chinese medicine composition of malignant tumor, have profit liver lung, beneficial gallbladder kidney, sharp the intestines and stomach, the bladder that relaxes, separate bad odor, rush down malignant tumor, and dredge the meridian passage, putrefaction removing promote the production of body fluid, pacify soul decide soul, set upright get rid of evils, detumescence, the beneficial god's that enriches blood effect.
Background technology
Malignant tumor is still unsolved so far difficult medical problem, and human beings'health in serious harm.
Doctor trained in Western medicine often adopts chemicotherapy method treatment tumor, but toxic and side effects is big, reactions such as edema, anorexia, pain, the reduction of blood phase index often occur, and insulting function of immune system, and tumour inhibiting rate is low.
The traditional Chinese medical science is in toxic herbs such as clinical normal use Mylabris, Scolopendra, Scorpio treatment cancer, and misapplication easily produces toxic reaction, and slow curative effect.The Chinese patent medicine that contains above-mentioned composition of present clinical use, very little to the late tumor patient effect, tumour inhibiting rate is low.
Modern medicine proves, bodily fuctions's imbalance, immunologic hypofunction is the main endogenous cause of ill that causes cancer, the traditional Chinese medical science notes improving the healthy energy of human body in the control tumor, promote QI-blood circulation, regulating functions of ZANG FU-organs, resist exopathogen, make the state of an illness controlled, focus is progressively dwindled, and reaches the purpose of treatment tumor.Because the healthy energy that the traditional Chinese medical science is paid attention to adjustment and escorted human body is demonstrating unique effect aspect the treatment tumor.
Summary of the invention
The objective of the invention is to bring into play traditional Chinese medical science combination drug, across-the-board regulation bodily fuctions's characteristics provide a kind of Chinese medicine composition for the treatment of cancer.The inventor is on the basis of clinical research for many years, and the flavour of a drug that used some seldom to use are at present formed this compositions, and it can the across-the-board regulation bodily fuctions, and enhancing immunity is dissolved virus, suppresses tumor growth, can be used in the various cancers of treatment.
The technical scheme of this compositions is as follows:
Compositions 1 is made by Moschus, cnidocampa flavescens walker, flesh and blood of felid, Monema flavescens Walker, nine flavor powder.The proportioning of each composition is: Moschus a little, or 0.1-0.5g, cnidocampa flavescens walker 0.3-1.5g, flesh and blood of felid 0.5-2g, Monema flavescens Walker 0.3-1.5g, nine flavor powder 2-10g.
Wherein nine flavor powder are: grape leaf 10-30%, Thallus Laminariae (Thallus Eckloniae) 10-30%, leaf of elm tree 6-18%, Radix et Caulis Opuntiae Dillenii 3-15%, Aloe 3-9%, Folium Pterocaryae 3-15%, Folium Populi Pseudo-simonii 3-15%, Folium Pruni 3-15%, ear 3-9%.
Compositions 2 is made by Moschus, cnidocampa flavescens walker, flesh and blood of felid, Monema flavescens Walker.The proportioning of each composition is: Moschus a little, or 0.1-0.5g, cnidocampa flavescens walker 0.3-1.5g, flesh and blood of felid 0.5-2g, Monema flavescens Walker 0.3-1.5g.
Above proportioning is the ratio range commonly used of each component, but the compositions that incomplete proportioning in this scope is made also is effective, compositions 1,2 can be that levigation behind each raw material drying is made powder, also can be after crude drug water or conventional solvent such as ethanol etc. are extracted, the common dosage form of making by the pharmaceutics common method, as decoction, electuary, tablet, oral liquid, honeyed pill, the watered pill etc., also can be the honeyed pill directly made with adjuvant after the raw material pulverizing, watered pill etc., or other dosage forms in addition.
The raw material of nine flavor powder is fresh and dried all can, can add with the form of raw material and unifiedly in the raw material of compositions 1 make above-mentioned medicament, also can pass through water or ethanol extraction, or without extraction, independently make above-mentioned each medicament, or regular dosage form in addition, when using, be used the proportioning of nine proportionings of distinguishing the flavor of powder and compositions 2 in can reference group compound 1 with compositions 2.
Compositions 3 is made by Moschus, flesh and blood of felid, nine flavor powder, 18 powder.Wherein the proportioning of each composition is: Moschus a little, or 0.1-0.5g, flesh and blood of felid 0.5-2g, nine flavor powder 1-5g, 18 powder 3-15g.
Wherein nine flavor compositions of powder and proportioning as mentioned above, 18 powder are: Herba Hedyotidis Diffusae 10-12%, Fructus Forsythiae 6-15%, Spica Prunellae 6-15%, Radix Asparagi 3-12%, Rhizoma Cyperi 3-9%, Herba Dianthi 3-9%, Radix Ginseng 3-9%, Radix Polygalae 3-9%, Radix Aucklandiae 3-9%, Rhizoma Pinelliae 3-9%, Bulbus Fritillariae Uninbracteatae 3-9%, Radix Rhapontici 3-9%, Ramulus Cinnamomi 3-9%, Radix Salviae Miltiorrhizae 3-9%, Herba Patriniae 3-9%, rhizoma sparganic 0.6-1.2%, Pseudobulbus cremastrae seu pleiones 0.6-1.2%, Rhizoma Belamcandae 0.6-1.5%.
Above proportioning is the ratio range commonly used of each component, but the compositions that incomplete proportioning in this scope is made also is effective, compositions 3 can be that levigation behind each raw material drying is made powder, also can be after crude drug water or conventional solvent such as ethanol etc. are extracted, the common dosage form of making by the pharmaceutics common method, as decoction, electuary, tablet, oral liquid, honeyed pill, the watered pill etc., also can be the honeyed pill directly made with adjuvant after the raw material pulverizing, watered pill etc., or other dosage forms in addition.
Nine flavor powder, 18 powder can add the unified medicament of making in the raw material of compositions 3 with the form of raw material, also can pass through water or ethanol extraction, or without extraction, independently make above-mentioned each medicament, or other regular dosage forms in addition, when using, be used by compositions 3 described proportioning raw materials and Moschus and flesh and blood of felid.
Used cnidocampa flavescens walker is a kind of tree worm in the compositions 1,2,3, is commonly called as " poplar favus ", gently fries or directly dries levigation; Monema flavescens Walker is the worm cocoon of " poplar favus ", i.e. the shell of pupa, and parching to brown dries levigation; Flesh and blood of felid is bone, the meat of felid such as cat, tiger etc.Its acquisition methods is: slaughter the back unhairing, the intestinal tripe is cleaned, and boils after the decomposition to taking off bone, and bone is pulverized, and together dries parching to brown, levigation with meat.
In above each technical scheme, Moschus plays the tying-in effect, and is not limited to strict consumption, and a little gets final product, and various combination is added and subtracted indivedual flavour of a drug and still belonged to scope of the present invention.
The specific embodiment
Embodiment 1: get the powder that raw material pulverizing is made nine flavor powder by following weight ratio: grape leaf 20%, Thallus Laminariae (Thallus Eckloniae) 20%, leaf of elm tree 15%, Radix et Caulis Opuntiae Dillenii 10%, Aloe (being Aloe) 5%, Folium Pterocaryae 10%, Folium Populi Pseudo-simonii 10%, Folium Pruni 5%, ear 5%
Above bright product raw material, dry back is ground and is made powder.
Embodiment 2: get the powder that raw material pulverizing is made compositions 1 by following weight ratio: Moschus 0.1g, cnidocampa flavescens walker 0.5g, the kindred 1g of cat, Monema flavescens Walker 0.5g, nine flavor powder 7g.
Get the dry product of above each raw material, the composition of nine flavor powder is pulverized the back mixing and is made powder as described in the embodiment 1.More than be a dosage.
Embodiment 3: get the powder that raw material pulverizing is made compositions 2 by following weight ratio: Moschus 0.1g, cnidocampa flavescens walker 0.3g, the kindred 1g of cat, Monema flavescens Walker 0.6g
Get the dry product of above each raw material, pulverize the back mixing and make powder.
Embodiment 4: get the powder that raw material pulverizing is made 18 powder by following weight ratio: Herba Hedyotidis Diffusae 15%, Fructus Forsythiae 10%, Spica Prunellae 10%, Radix Asparagi 7%, Rhizoma Cyperi 5%, Herba Dianthi 5%, Radix Ginseng 5%, Radix Polygalae 5%, the Radix Aucklandiae 5%, the Rhizoma Pinelliae 5%, Bulbus Fritillariae Uninbracteatae 5%, Radix Rhapontici 5%, Ramulus Cinnamomi 5%, Radix Salviae Miltiorrhizae 5%, Herba Patriniae 5%, rhizoma sparganic 1%, Pseudobulbus cremastrae seu pleiones 1%, Rhizoma Belamcandae 1%.
Embodiment 5: get the powder that raw material pulverizing is made compositions 3 by following weight ratio: Moschus 0.1g, the kindred 1g of cat, nine flavor powder 2g, 18 powder 6g
Get the dry product of above each raw material, the composition of nine flavor powder, 18 powder as described in the embodiment 1,4, is pulverized the back mixing and is made powder respectively.More than be a dosage.
Five. clinical principium is summed up
Pharmaceutical composition 1 of the present invention and compositions 3 are made universe spirit A, B electuary respectively, through clinical use for many years, can effectively improve clinical symptoms, suppress the tumor body, curative effect is reliable, now just being carried out the II clinical trial phase of standard by Cancer Hospital of Chinese Academy of Medical Sciences, below is that preliminary clinical observation in early stage is summed up:
One. this medicine of physical data is made use for many years by oneself, the patient of treatment from seven years old to eight teen ages.All turn out to be cancer through clinical means such as CT examination, section, chemical examinations.Routine gastric cancer, esophageal carcinoma case are added up surplus now collecting 30.
Two. Therapeutic Method is taken medicine 3 times every day, divides two stages, and the phase I is taken compositions 1 earlier, and totally three days, take compositions 3 again, totally ten two days, repeat this circulation primary again, just be a course of treatment.
Three. efficacy assessment standard adopts self treatment front and back symptom contrast, presses the objective efficacy assessment standard evaluation of cancer therapy drug clinical research guideline solid tumor observing effect.
The positive sign of clinical cure symptom and inspection disappears, and diet, spirit, blood pressure, cell ratio recover normal, recover certain work capacity.
The produce effects symptom disappears substantially, and focus is dwindled, and every index of physical examination takes a turn for the better.
Effectively symptom makes moderate progress, and focus is basicly stable.
Invalid symptom does not change or worsens.
Through observing, took medicine back 3-7 days, the symptom of most patients obviously alleviates or disappears as edema, anorexia, dysphagia, vomiting, pain etc., and spirit takes a turn for the better, appetite increases, blood pressure, blood equate the index improvement, and symptom releasing rate can reach 97% in 15 days, takes medicine 2-3 after the course of treatment, observe the tumor body and dwindle, tumour inhibiting rate is more than 40-50%.Total effective rate is 97% by statistics.
Chinese medicine composition 1,3 of the present invention shows through institute of oncology, Academy of Medical Sciences animal test results: hepatocarcinoma, nude mice people tumor (colon) tumour inhibiting rate are more than 40-50%; The animal experiment demonstration has no side effect.
Clinical in recent years use finds that compositions of the present invention has following characteristics:
1. the various tumors that can treat the early, middle and late phase applied widely are particularly outstanding to the tumor of digestion, secretion and respiratory system such as gastric cancer, intestinal cancer, esophageal carcinoma, cancer of pancreas, hepatocarcinoma, pulmonary carcinoma effect.
2. have definite curative effect and can suppress the tumor body, and can improve that tumor causes rapidly or because put, symptom that chemotherapy causes, low mutually inferior as edema, anorexia, dysphagia, vomiting, pain, hydrops, blood, can take effect after taking medicine 3, symptom releasing rate can reach 97% in 15 days.Can treat infantile tumour, with the various tumors of operation partner treatment middle and advanced stage, can prolong the life of utmost point patient with advanced cancer, improve its quality of life, tumour inhibiting rate is more than 40-50%.
3. the effect that has prophylaxis of tumours.
4. human body is not produced toxic and side effects.
Claims (7)
1. the compositions of treatment tumor is characterized in that being made up of compositions 1 and compositions 3, wherein
Compositions 1 is made by following materials of weight proportions: Moschus 0.1-0.5g, cnidocampa flavescens walker 0.3-1.5g, flesh and blood of felid 0.5-2g, Monema flavescens Walker 0.3-1.5g, nine flavor powder 2-10g;
Compositions 3 is made by following materials of weight proportions: Moschus 0.1-0.5g, flesh and blood of felid 0.5-2g, nine flavor powder 1-5g, 18 powder 3-15g;
Wherein nine flavor powder are made by following materials of weight proportions: grape leaf 10-30%, Thallus Laminariae (Thallus Eckloniae) 10-30%, leaf of elm tree 6-18%, Radix et Caulis Opuntiae Dillenii 3-15%, Aloe 3-9%, Folium Pterocaryae 3-15%, Folium Populi Pseudo-simonii 3-15%, Folium Pruni 3-15%, ear 3-9%;
18 powder are made by following materials of weight proportions: Herba Hedyotidis Diffusae 10-12%, Fructus Forsythiae 6-15%, Spica Prunellae 6-15%, Radix Asparagi 3-12%, Rhizoma Cyperi 3-9%, Herba Dianthi 3-9%, Radix Ginseng 3-9%, Radix Polygalae 3-9%, Radix Aucklandiae 3-9%, Rhizoma Pinelliae 3-9%, Bulbus Fritillariae Uninbracteatae 3-9%, Radix Rhapontici 3-9%, Ramulus Cinnamomi 3-9%, Radix Salviae Miltiorrhizae 3-9%, Herba Patriniae 3-9%, rhizoma sparganic 0.6-1.2%, Pseudobulbus cremastrae seu pleiones 0.6-1.2%, Rhizoma Belamcandae 0.6-1.5%.
2. the compositions of treatment tumor according to claim 1 is characterized in that compositions 1 made by following materials of weight proportions: Moschus 0.1g, cnidocampa flavescens walker 0.5g, flesh and blood of felid 1g, Monema flavescens Walker 0.5g, nine flavor powder 7g.
3. the compositions of treatment tumor according to claim 1 is characterized in that compositions 3 made by following materials of weight proportions: Moschus 0.1g, flesh and blood of felid 1g, nine flavor powder 2g, 18 powder 6g.
4. the compositions of treatment tumor according to claim 2 is characterized in that compositions 3 made by following materials of weight proportions: Moschus 0.1g, flesh and blood of felid 1g, nine flavor powder 2g, 18 powder 6g.
5. according to the compositions of the described treatment tumor of arbitrary claim among the claim 1-4, it is characterized in that nine flavor powder are made by following materials of weight proportions: grape leaf 20%, Thallus Laminariae (Thallus Eckloniae) 20%, leaf of elm tree 15%, Radix et Caulis Opuntiae Dillenii 10%, Aloe 5%, Folium Pterocaryae 10%, Folium Populi Pseudo-simonii 10%, Folium Pruni 5%, ear 5%.
6. according to the compositions of the described treatment tumor of arbitrary claim among the claim 1-4, it is characterized in that 18 powder are made by following materials of weight proportions: Herba Hedyotidis Diffusae 15%, Fructus Forsythiae 10%, Spica Prunellae 10%, Radix Asparagi 7%, Rhizoma Cyperi 5%, Herba Dianthi 5%, Radix Ginseng 5%, Radix Polygalae 5%, the Radix Aucklandiae 5%, the Rhizoma Pinelliae 5%, Bulbus Fritillariae Uninbracteatae 5%, Radix Rhapontici 5%, Ramulus Cinnamomi 5%, Radix Salviae Miltiorrhizae 5%, Herba Patriniae 5%, rhizoma sparganic 1%, Pseudobulbus cremastrae seu pleiones 1%, Rhizoma Belamcandae 1%.
7. the compositions of treatment tumor according to claim 5 is characterized in that 18 powder are made by following materials of weight proportions: Herba Hedyotidis Diffusae 15%, Fructus Forsythiae 10%, Spica Prunellae 10%, Radix Asparagi 7%, Rhizoma Cyperi 5%, Herba Dianthi 5%, Radix Ginseng 5%, Radix Polygalae 5%, the Radix Aucklandiae 5%, the Rhizoma Pinelliae 5%, Bulbus Fritillariae Uninbracteatae 5%, Radix Rhapontici 5%, Ramulus Cinnamomi 5%, Radix Salviae Miltiorrhizae 5%, Herba Patriniae 5%, rhizoma sparganic 1%, Pseudobulbus cremastrae seu pleiones 1%, Rhizoma Belamcandae 1%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB01139823XA CN1180811C (en) | 2001-11-30 | 2001-11-30 | Chinese medicine composition for treating tumor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB01139823XA CN1180811C (en) | 2001-11-30 | 2001-11-30 | Chinese medicine composition for treating tumor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1421222A CN1421222A (en) | 2003-06-04 |
CN1180811C true CN1180811C (en) | 2004-12-22 |
Family
ID=4675441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB01139823XA Expired - Fee Related CN1180811C (en) | 2001-11-30 | 2001-11-30 | Chinese medicine composition for treating tumor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1180811C (en) |
-
2001
- 2001-11-30 CN CNB01139823XA patent/CN1180811C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1421222A (en) | 2003-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103734548B (en) | Feedstuff for treating swine dyspepsia and preparation method thereof | |
CN101590168B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
CN1682842A (en) | Chinese medicine composition for diminishing-inflammation and detoxication and its preparing method and use | |
CN101590184A (en) | A kind of Chinese medicine composition that is used for the treatment of gout and preparation method thereof | |
CN107468768B (en) | Qiang medicine composition and application thereof | |
CN108186899A (en) | A kind of Chinese medicine composition for treating tumour and preparation method and application | |
CN102772611B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
CN101590167B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
CN101590169B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
WO2021042275A1 (en) | Traditional chinese medicine composition for treating osteoarthritis | |
CN1272027C (en) | Desmodium preparation for treating urinary calculus, infection and cholelithiasis cholecy stolithiasis and chole cystitis and its production method | |
CN1180811C (en) | Chinese medicine composition for treating tumor | |
CN101028482A (en) | Stomach-clearing pill | |
CN1814131A (en) | Chinese medicine for treating astriction and preparing method | |
CN1207012C (en) | Medicine for treating digestive system disease and tumor and preparation method thereof | |
CN1141139C (en) | Anti-cancer medicine and its preparation method | |
CN104857422B (en) | It treats the composition of colorectal cancer and is used to prepare the purposes for the treatment of large intestine cancer drug | |
CN114470134B (en) | Compound traditional Chinese medicine composition for treating chronic atrophic gastritis and application thereof | |
CN106728505A (en) | A kind of Chinese medicine composition for treating pig founder | |
CN1861119B (en) | Traditional Chinese medicine for treating rheumatosis and its preparation method | |
CN1927349A (en) | Traditional Chinese medicine for treating rheumatism and its preparing process | |
CN1064536C (en) | Full-divergence promoting medicine for curing fourth-phase carcinoma of stomach and its processing method | |
CN106344755B (en) | Compound medicine for treating stomach diseases and preparation method thereof | |
CN1166383C (en) | Medicine for treating tumor in digestive tract and its prepn | |
CN114767803A (en) | Dendrobium officinale traditional Chinese medicine composition for preventing and treating hyperuricemia by reducing kidney PDZK1 protein, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041222 Termination date: 20121130 |